Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Immunofoco to Start US Trial of CAR-T for Gastrointestinal Tumors

publication date: Feb 23, 2024

Shanghai Immunofoco was approved to begin a US Phase I trial of IMC001, an EpCAM-targeting autologous CAR-T cell product to treat EpCAM-positive advanced gastrointestinal tumors. The company was already approved to start China trials of the candidate. The US trial will enroll patients with advanced gastric cancer and gastroesophageal junction adenocarcinoma. EpCAM is a biomarker for circulating tumor cells, which are highly expressed in both primary and metastatic lesions of gastrointestinal tumors, while having only low expression in normal tissues. Immunofoco develops cell therapy products for solid tumors. More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital